These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

359 related articles for article (PubMed ID: 15316096)

  • 1. Impact of chronic allograft nephropathy and subsequent modifications of immunosuppressive therapy on late graft outcomes in renal transplantation.
    Montagnino G; Banfi G; Campise MR; Passerini P; Aroldi A; Cesana BM; Ponticelli C
    Nephrol Dial Transplant; 2004 Oct; 19(10):2622-9. PubMed ID: 15316096
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detrimental effects of cyclosporin A on long-term graft survival in familial Mediterranean fever renal allograft recipients: experience of two transplantation centers.
    Shabtai M; Ben-Haim M; Zemer D; Malinger-Saavedra P; Rosin D; Kuriansky J; Lustig S; Shabtai EL; Shapira Z; Ayalon A
    Isr Med Assoc J; 2002 Nov; 4(11 Suppl):935-9. PubMed ID: 12455184
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus.
    Bumbea V; Kamar N; Ribes D; Esposito L; Modesto A; Guitard J; Nasou G; Durand D; Rostaing L
    Nephrol Dial Transplant; 2005 Nov; 20(11):2517-23. PubMed ID: 15985508
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of tacrolimus compared with cyclosporin A microemulsion in renal transplantation: 2 year follow-up results.
    Krämer BK; Montagnino G; Del Castillo D; Margreiter R; Sperschneider H; Olbricht CJ; Krüger B; Ortuño J; Köhler H; Kunzendorf U; Stummvoll HK; Tabernero JM; Mühlbacher F; Rivero M; Arias M;
    Nephrol Dial Transplant; 2005 May; 20(5):968-73. PubMed ID: 15741208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunosuppression modifications and graft outcome in patients with chronic allograft nephropathy.
    El-Agroudy AE; El-Dahshan K; Mahmoud K; Ismail AM; El-Baz M; Shokeir AA; Ghoneim MA
    Exp Clin Transplant; 2008 Sep; 6(3):203-10. PubMed ID: 18954298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sirolimus-based triple immunosupression with antithymocyte globulin induction in expanded criteria donor kidney transplantation.
    Uslu A; Nart A; Taşli FA; Postaci H; Aykas A; Doğan M; Sahin T
    Nephrology (Carlton); 2008 Feb; 13(1):80-6. PubMed ID: 18199109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early withdrawal of cyclosporine A improves 1-year kidney graft structure and function in sirolimus-treated patients.
    Stallone G; Di Paolo S; Schena A; Infante B; Grandaliano G; Battaglia M; Gesualdo L; Schena FP
    Transplantation; 2003 Apr; 75(7):998-1003. PubMed ID: 12698087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low serum magnesium is associated with decreased graft survival in patients with chronic cyclosporin nephrotoxicity.
    Holzmacher R; Kendziorski C; Michael Hofman R; Jaffery J; Becker B; Djamali A
    Nephrol Dial Transplant; 2005 Jul; 20(7):1456-62. PubMed ID: 15840674
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beneficial effect of concomitant induction with antilymphoblast globulin, cyclosporine, and steroids on long-term renal allograft outcome.
    Koga A; Moreso FJ; Seron D; Gil-Vernet S; Cruzado JM; Castelao AM; Grinyó JM
    Transplant Proc; 2004 Jun; 36(5):1305-7. PubMed ID: 15251318
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Minimization of maintenance immunosuppression early after renal transplantation: an interim analysis.
    Bemelman FJ; de Maar EF; Press RR; van Kan HJ; ten Berge IJ; Homan van der Heide JJ; de Fijter HW
    Transplantation; 2009 Aug; 88(3):421-8. PubMed ID: 19667948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk factors of long-term graft loss in renal transplant recipients with chronic allograft dysfunction.
    Khalkhali HR; Ghafari A; Hajizadeh E; Kazemnejad A
    Exp Clin Transplant; 2010 Dec; 8(4):277-82. PubMed ID: 21143092
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of immunosuppressive regimens on graft survival and secondary outcomes after kidney transplantation.
    Opelz G; Döhler B;
    Transplantation; 2009 Mar; 87(6):795-802. PubMed ID: 19300179
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Variable cyclosporine exposure: a risk factor for chronic allograft nephropathy and graft loss?
    He X; Johnston A
    Transplant Proc; 2004 Jun; 36(5):1321-6. PubMed ID: 15251323
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tacrolimus as secondary intervention vs. cyclosporine continuation in patients at risk for chronic renal allograft failure.
    Waid T;
    Clin Transplant; 2005 Oct; 19(5):573-80. PubMed ID: 16146546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blockade of the renin-angiotensin system increases graft survival in patients with chronic allograft nephropathy.
    Artz MA; Hilbrands LB; Borm G; Assmann KJ; Wetzels JF
    Nephrol Dial Transplant; 2004 Nov; 19(11):2852-7. PubMed ID: 15466882
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stable kidney function in the second decade after kidney transplantation while on cyclosporine-based immunosuppression.
    Kandaswamy R; Humar A; Casingal V; Gillingham KJ; Ibrahim H; Matas AJ
    Transplantation; 2007 Mar; 83(6):722-6. PubMed ID: 17414704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term kidney transplant outcomes in patients receiving oil-based or microemulsion formulations of cyclosporine.
    Medina-Pestana JO; Felipe CR; Park SI; Machado PG; Garcia R; Spinelli G; Silva LA; Santos CF; Tedesco-Silva H
    Transplant Proc; 2004 Mar; 36(2 Suppl):74S-79S. PubMed ID: 15041311
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term use of cyclosporine A does not adversely impact on clinical outcomes following renal transplantation.
    Lewis RM
    Kidney Int Suppl; 1995 Dec; 52():S75-8. PubMed ID: 8587289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Five-year study of tacrolimus as secondary intervention versus continuation of cyclosporine in renal transplant patients at risk for chronic renal allograft failure.
    Jevnikar A; Arlen D; Barrett B; Boucher A; Cardella C; Cockfield SM; Rush D; Paraskevas S; Shapiro J; Shoker A; Yilmaz S; Zaltzman JS; Kiberd B
    Transplantation; 2008 Oct; 86(7):953-60. PubMed ID: 18852662
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renal function: defining long-term success.
    Pascual J; Marcén R; Ortuño J
    Nephrol Dial Transplant; 2004 Dec; 19 Suppl 6():vi3-vi7. PubMed ID: 15575023
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.